Cowan Chad 4

What Happened

• Chad Cowan, Chief Scientific Officer of Century Therapeutics (IPSC), received equity awards on Feb 2, 2026: 135,000 restricted stock units (RSUs) and 265,000 derivative awards (stock option-style). Both awards are reported with an acquisition price of $0 and therefore show $0 cash paid on the Form 4.

Key Details

• Transaction date: Feb 2, 2026; Form 4 filed Feb 4, 2026 (covers the Feb 2 grants).
• Award amounts: 135,000 RSUs; 265,000 derivative awards (stock options).
• Reported acquisition price/value: $0 for both grants (common for issued awards).
• Shares owned after transaction: not disclosed in this filing.
• Footnotes of note:
  • F1: The 135,000 RSUs each convert to one share and vest 25% on Feb 2, 2027, then the remaining 75% vests quarterly over the following three years; RSUs will be settled in shares upon vesting.
  • F3: The 265,000 derivative award vests 25% on Feb 2, 2027, then the remaining 75% in 36 equal monthly installments (i.e., multi-year service-based vesting).
  • F2: Notes certain shares are held by the Cowan Investment Nominee Trust and the reporting person disclaims beneficial ownership except for any pecuniary interest.

Context

• These are grants/awards (not open-market purchases or sales). RSUs convert to shares only upon vesting; options (derivative awards) require future vesting and likely exercise before becoming stock—neither provides immediate sale proceeds.
• Such grants are routine compensation for executives and should be read as long-term incentive awards rather than immediate market bets; the filing does not disclose any sale or cash exercise tied to these awards.